Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
As a part of the royalty agreement, Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a combination therapy indication for the compound.
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.